A Phase II Trial of Bortezomib (Velcade) After Allogenic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Sep 2010 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 28 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.